Menten AI

Company profile

About Menten AI

Menten AI is a biotechnology company pioneering the use of generative artificial intelligence to design cyclic peptide therapeutics for drug targets that lie beyond the reach of traditional small molecules and biologics. The company's proprietary platform, MAUD 1.0 (Multi-parametric AI for Unbiased Design), combines generative AI, physics-based modeling, and quantum simulations to design peptide macrocycles from scratch with atomic precision. Unlike traditional machine learning approaches that require large training datasets, MAUD 1.0 leverages physics-informed reinforcement learning to perform de novo design of cyclic peptides. The platform addresses a critical gap in drug discovery: up to 80% of drug targets, particularly protein-protein interfaces, cannot be effectively targeted by conventional therapeutics. Peptide macrocycles occupy a unique therapeutic space between small molecules and biologics, offering advantages such as high selectivity, low toxicity, and the ability to bind protein-protein interfaces. MAUD 1.0 has demonstrated the ability to design peptides with nanomolar-level potency, oral bioavailability exceeding 18%, cell permeability, and hit rates above 90%. Menten AI partners with top-10 pharmaceutical companies and is backed by leading venture capital firms. The company's technology enables multiple applications including oral peptides, cell-permeable peptides for intracellular targets, molecular glues, bi-specifics, and computational optimization. Their approach accelerates the preclinical discovery pipeline by designing and optimizing drug-like peptides more efficiently than traditional screening methods, expanding the accessible chemical space for therapeutic development.

Company description · Menten AI official website